PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 29 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Leaf extracts, particularly the chloroform extract, dose-dependently inhibited the proliferation of S180 cells [PMID:27525864].
28-carboxyl oleane triterpenes from the resin showed significant inhibition of ADP-induced platelet aggregation [PMID:21605635].
Reportedly used in combination with Vaccaria segetalis; however, no well-performed clinical trials in English have been reported on the oral effect in humans [PMID:37094052].
Pregnancy & lactation
Evidence summary
PubMed sources
- 1.PMID: 37094052 (2006) — Genome-wide identification and expression analysis of late embryogenesis abundant (LEA) genes reveal their potential roles in somatic embryogenesis in hybrid sweetgum (Liquidambar styraciflua × Liquidambar formosana). · Forestry research
- 2.PMID: 33556839 (2021) — Pentacyclic Triterpenes from the resin of Liquidambar formosana have anti-angiogenic properties. · Phytochemistry
- 3.PMID: 27525864 (2016) — Effect of the extract from leaves of Liquidambar formosana Hance on S180 cells. · Genetics and molecular research : GMR
- 4.PMID: 40460252 (2025) — Genomic insights into the evolution of Chinese sweetgum and its autumn leaf coloration. · Plant physiology
- 5.PMID: 36672904 (2023)